MTF Biologics, in partnership with biologic solutions provider Kolosis BIO, has introduced two new allograft tissues designed to aid cardiac surgeons in complex procedures.
The ATLAS Sternal Repair Matrix and the IKON Allograft Surgical Matrix are set to enhance patient outcomes by providing solutions for sternal fusion and soft tissue repair, respectively, particularly in high-risk individuals.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Comprising a demineralised cortical bone allograft, ATLAS will be placed between the sternal edges before closure to aid in fusion and stabilisation.
It has been processed to retain native growth factors and is evaluated for osteoinductive potential, offering an osteoconductive scaffold that supports quick hydration and bone formation.
The IKON Allograft Surgical Matrix aids in incision management and sternal closure.
It is designed to minimise bioburden and inflammation while promoting the restoration of blood supply.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMTF Biologics noted that this matrix is applied within subcutaneous tissue following a sternal closure and features a collagen structure that supports wound closure in high-risk individuals.
MTF Biologics orthopaedic franchise general manager and vice-president Brad Bailey said: “The MTF Biologics team is pleased to apply our proven allografts, developed in collaboration with surgeons across the nation, to transform sternal fusion and wound healing in the cardiac space.
“ATLAS and IKON will support clinicians caring for patients with complex challenges who are undergoing high-risk cardiac procedures. The Kolosis BIO team is an ideal partner to bring these innovative solutions to this market with us.”
Kolosis BIO focuses on commercialising technologies across various verticals in the surgical biologics space.
Kolosis BIO CEO Collin Begley said: “For Kolosis, launching ATLAS and IKON in cardiac surgery is an exciting step into a new market, furthering our position as the premier pure-play biologics provider.”
